316 related articles for article (PubMed ID: 38269619)
41. Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy.
Apollonio B; Ioannou N; Papazoglou D; Ramsay AG
Front Oncol; 2021; 11():626818. PubMed ID: 33842331
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
Front Immunol; 2021; 12():799455. PubMed ID: 35069581
[TBL] [Abstract][Full Text] [Related]
43. Qin Huang formula enhances the effect of Adriamycin in B-cell lymphoma via increasing tumor infiltrating lymphocytes by targeting toll-like receptor signaling pathway.
Li W; Lv L; Ruan M; Xu J; Zhu W; Li Q; Jiang X; Zheng L; Zhu W
BMC Complement Med Ther; 2022 Jul; 22(1):185. PubMed ID: 35818037
[TBL] [Abstract][Full Text] [Related]
44. Targeting DNA Repair, Cell Cycle, and Tumor Microenvironment in B Cell Lymphoma.
Bröckelmann PJ; de Jong MRW; Jachimowicz RD
Cells; 2020 Oct; 9(10):. PubMed ID: 33066395
[TBL] [Abstract][Full Text] [Related]
45. Antifibrotic therapy to normalize the tumor microenvironment.
Hauge A; Rofstad EK
J Transl Med; 2020 May; 18(1):207. PubMed ID: 32434573
[TBL] [Abstract][Full Text] [Related]
46. Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment - New Findings and Future Perspectives.
Nagl L; Horvath L; Pircher A; Wolf D
Front Cell Dev Biol; 2020; 8():766. PubMed ID: 32974337
[TBL] [Abstract][Full Text] [Related]
47. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
Front Immunol; 2022; 13():974581. PubMed ID: 36159860
[TBL] [Abstract][Full Text] [Related]
48. Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression.
Cao X; Wang Y; Zhang W; Zhong X; Gunes EG; Dang J; Wang J; Epstein AL; Querfeld C; Sun Z; Rosen ST; Feng M
Blood; 2022 Jun; 139(22):3290-3302. PubMed ID: 35134139
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic challenges in peripheral T-cell lymphoma.
Luan Y; Li X; Luan Y; Luo J; Dong Q; Ye S; Li Y; Li Y; Jia L; Yang J; Yang DH
Mol Cancer; 2024 Jan; 23(1):2. PubMed ID: 38178117
[TBL] [Abstract][Full Text] [Related]
50. Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments.
Gsottberger F; Brandl C; Wendland K; Petkovic S; Emmerich C; Erber R; Geppert C; Hartmann A; Mackensen A; Nitschke L; Müller F
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638774
[TBL] [Abstract][Full Text] [Related]
51. Role of tumor-associated macrophages in hematological malignancies.
Komohara Y; Niino D; Ohnishi K; Ohshima K; Takeya M
Pathol Int; 2015 Apr; 65(4):170-6. PubMed ID: 25707506
[TBL] [Abstract][Full Text] [Related]
52. The tumor microenvironment: shaping cancer progression and treatment response.
Desai SA; Patel VP; Bhosle KP; Nagare SD; Thombare KC
J Chemother; 2024 Jan; ():1-30. PubMed ID: 38179655
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic Targeting of the Tumor Microenvironment.
Bejarano L; Jordāo MJC; Joyce JA
Cancer Discov; 2021 Apr; 11(4):933-959. PubMed ID: 33811125
[TBL] [Abstract][Full Text] [Related]
54. Wnt Signaling in the Tumor Microenvironment.
Ruan Y; Ogana H; Gang E; Kim HN; Kim YM
Adv Exp Med Biol; 2021; 1270():107-121. PubMed ID: 33123996
[TBL] [Abstract][Full Text] [Related]
55. Characterization and Manipulation of the Crosstalk Between Dendritic and Natural Killer Cells Within the Tumor Microenvironment.
Jacobs B; Gebel V; Heger L; Grèze V; Schild H; Dudziak D; Ullrich E
Front Immunol; 2021; 12():670540. PubMed ID: 34054844
[TBL] [Abstract][Full Text] [Related]
56. The Janus Face of Tumor Microenvironment Targeted by Immunotherapy.
Buoncervello M; Gabriele L; Toschi E
Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31484464
[TBL] [Abstract][Full Text] [Related]
57. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
Eskandari-Malayeri F; Rezaei M
Front Immunol; 2022; 13():996145. PubMed ID: 36275750
[TBL] [Abstract][Full Text] [Related]
58. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
59. TME-Related Biomimetic Strategies Against Cancer.
Peng C; Xu Y; Wu J; Wu D; Zhou L; Xia X
Int J Nanomedicine; 2024; 19():109-135. PubMed ID: 38192633
[TBL] [Abstract][Full Text] [Related]
60. Structural Biology of the Tumor Microenvironment.
Freeman JW
Adv Exp Med Biol; 2021; 1350():91-100. PubMed ID: 34888845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
